Goldenwell Biotech (GWLL) Liabilities and Shareholders Equity (2019 - 2025)
Goldenwell Biotech (GWLL) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $220410.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 22.84% year-over-year to $220410.0, compared with a TTM value of $887812.0 through Sep 2025, up 10.03%, and an annual FY2024 reading of $224192.0, down 1.71% over the prior year.
- Liabilities and Shareholders Equity was $220410.0 for Q3 2025 at Goldenwell Biotech, down from $251295.0 in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $509176.0 in Q2 2021 and bottomed at $179432.0 in Q3 2024.
- Average Liabilities and Shareholders Equity over 5 years is $278007.5, with a median of $228094.0 recorded in 2023.
- The sharpest move saw Liabilities and Shareholders Equity soared 93.92% in 2021, then plummeted 46.11% in 2022.
- Year by year, Liabilities and Shareholders Equity stood at $460979.0 in 2021, then tumbled by 46.11% to $248400.0 in 2022, then dropped by 8.17% to $228094.0 in 2023, then decreased by 1.71% to $224192.0 in 2024, then dropped by 1.69% to $220410.0 in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for GWLL at $220410.0 in Q3 2025, $251295.0 in Q2 2025, and $191915.0 in Q1 2025.